Export financials
InspireMD (NSPR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

InspireMD Financial Statements 2025-2008 | NSPR
Annual Financial Statements InspireMD
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
115 M | 75.1 M | 63.6 M | 8.74 M | 22.2 M | 15.7 M | 2.47 M | 4.15 M | 371 K | 99.1 K | 116 K | 900 K | 2.3 M | 1.63 B | 2.92 M | - | - | - |
Shares |
64.3 M | 41.9 M | 24.3 M | 7.87 M | 7.35 M | 1.51 M | 139 K | 30.8 K | 1.98 K | 56 | 11 | 6 | 5 | 1.91 K | 2 | 49.9 M | - | - |
Historical Prices |
1.79 | 1.79 | 2.62 | 1.11 | 3.02 | 5.1 | 16.2 | 120 | 97.5 | 1.88 K | 16.5 K | 146 K | 461 K | 731 K | 1.64 M | - | - | - |
Net Income |
-48.8 M | -32 M | -19.9 M | -18.5 M | -14.9 M | -10.5 M | -10 M | -7.24 M | -8.44 M | -8.46 M | -15.6 M | -25.1 M | -29.3 M | -17.6 M | -14.7 M | -3.42 M | -2.72 M | - |
Revenue |
8.98 M | 7.01 M | 6.2 M | 5.17 M | 4.5 M | 2.48 M | 3.72 M | 3.6 M | 2.76 M | 1.89 M | 2.31 M | 2.82 M | 4.87 M | 5.35 M | 6 M | 4.95 M | 3.41 M | - |
Cost of Revenue |
6.33 M | 5.5 M | 4.4 M | 4.05 M | 3.74 M | 2.4 M | 2.96 M | 2.61 M | 2.18 M | 1.79 M | 2.61 M | 2.03 M | 2.28 M | 2.85 M | 3.01 M | 2.7 M | 2.29 M | - |
Gross Profit |
2.65 M | 1.51 M | 1.81 M | 1.12 M | 754 K | 83 K | 756 K | 995 K | 585 K | 102 K | -296 K | 784 K | 2.59 M | 2.5 M | 2.99 M | 2.25 M | 1.12 M | - |
Operating Income |
-49.6 M | -33.5 M | -21.1 M | -18.7 M | -14.7 M | -10.4 M | -9.82 M | -7.61 M | -8.23 M | -7.65 M | -14.5 M | -23.7 M | -15.1 M | -17.5 M | -13.7 M | -3.22 M | -2.72 M | - |
Interest Expense |
- | - | - | - | - | - | 200 K | -371 K | 119 K | 721 K | 1.04 M | 1.41 M | 4.27 M | 1.24 M | 730 K | 105 K | 221 K | - |
EBITDA |
426 M | 246 M | 211 M | 169 M | -14.6 M | -10.2 M | -9.66 M | -7.46 M | -8.05 M | -7.46 M | -13.3 M | -23.4 M | -14.9 M | -17.4 M | -13.6 M | -3.13 M | -2.63 M | - |
Operating Expenses |
52.3 M | 35 M | 23 M | 19.8 M | 15.5 M | 10.5 M | 10.6 M | 8.61 M | 8.82 M | 7.75 M | 13.2 M | 24.5 M | 17.7 M | 20 M | 16.7 M | 5.47 M | 3.84 M | - |
General and Administrative Expenses |
20.7 M | 15.3 M | 11.1 M | 8.36 M | 7.4 M | 6.13 M | 5.22 M | 4.83 M | 5.18 M | 5 M | 6.39 M | 9.12 M | 8.97 M | 13.9 M | 12.3 M | 2.9 M | 1.47 M | - |
All numbers in USD currency
Quarterly Income Statement InspireMD
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
83.8 M | 73.5 M | 51 M | 50 M | 26.6 M | 48.4 M | 35.9 M | 34.2 M | 21.8 M | 34 M | 21.1 M | 8.09 M | 8.33 M | 7.84 M | 7.81 M | 7.8 M | 8.3 M | 7.74 M | 7.7 M | 6.12 M | 3.28 M | 2.33 M | 845 K | 308 K | 3.92 M | 1.65 M | 1.38 M | 840 K | 38.4 M | 815 K | 135 K | 45.1 K | 1.48 M | 318 K | 314 K | 113 K | 42.7 K | 2.34 M | 427 K | 322 K | 314 K | 305 K | 7.6 M | 4.99 M | 4.14 M | 3.46 M | 34.1 M | 34.1 M | 34 M | 34 M | 31 M | 34 M | 17.7 M | 17.1 M | 17.4 M | 17 M | 16.7 M | 65.3 M | 64.2 M | 68.2 M |
Net Income |
-13.7 M | -12.7 M | -13.2 M | -11.2 M | - | -7.89 M | -7.91 M | -7.03 M | - | -5.18 M | -5.08 M | -4.26 M | - | -4.53 M | -4.64 M | -4.48 M | - | -4.07 M | -3.51 M | -3.24 M | - | -2.23 M | -2.48 M | -1.98 M | - | -2.07 M | -2.21 M | -3.21 M | - | -2.01 M | -627 K | -2.39 M | - | -2.09 M | -2.29 M | -2.56 M | - | -2 M | -1.95 M | -2.25 M | - | -3.64 M | -3.88 M | -5.21 M | - | -6.78 M | -7.56 M | -5.97 M | - | -3.94 M | -14.9 M | -3.94 M | -1.92 M | -7.51 M | -9.43 M | -7.51 M | -8.23 M | -2.28 M | -2.25 M | -1.9 M |
Revenue |
3.4 M | 2.52 M | 1.78 M | 1.53 M | - | 1.81 M | 1.74 M | 1.51 M | - | 1.56 M | 1.65 M | 1.24 M | - | 1.43 M | 1.53 M | 1.18 M | - | 1.07 M | 1.04 M | 1.01 M | - | 980 K | 313 K | 1.03 M | - | 939 K | 1.35 M | 415 K | - | 769 K | 1 M | 1.01 M | - | 718 K | 640 K | 569 K | - | 469 K | 540 K | 563 K | - | 632 K | 685 K | 477 K | - | 273 K | 193 K | 1.48 M | - | 1.55 M | 1.5 M | 1.55 M | 1.35 M | 509 K | 1.86 M | 509 K | 1.29 M | 1.99 M | 1.04 M | 1.69 M |
Cost of Revenue |
2.71 M | 1.66 M | 1.46 M | 1.24 M | - | 1.4 M | 1.41 M | 1.22 M | - | 1.12 M | 1.16 M | 866 K | - | 1.06 M | 1.1 M | 1.06 M | - | 979 K | 776 K | 900 K | - | 682 K | 433 K | 739 K | - | 811 K | 912 K | 488 K | - | 571 K | 726 K | 714 K | - | 565 K | 493 K | 495 K | - | 439 K | 478 K | 497 K | - | 543 K | 897 K | 514 K | - | 349 K | 584 K | 625 K | - | 750 K | 832 K | 750 K | 547 K | 230 K | 777 K | 230 K | 671 K | 801 K | 640 K | 899 K |
Gross Profit |
687 K | 864 K | 313 K | 292 K | - | 414 K | 331 K | 292 K | - | 438 K | 491 K | 373 K | - | 366 K | 431 K | 122 K | - | 92 K | 262 K | 106 K | - | 298 K | -120 K | 295 K | - | 128 K | 442 K | -73 K | - | 198 K | 277 K | 293 K | - | 153 K | 147 K | 74 K | - | 30 K | 62 K | 66 K | - | 89 K | -212 K | -37 K | - | -76 K | -391 K | 857 K | - | 802 K | 668 K | 802 K | 803 K | 279 K | 1.08 M | 279 K | 621 K | 1.18 M | 400 K | 787 K |
Operating Income |
-14 M | -13.1 M | -13 M | -11.5 M | - | -8.46 M | -8.26 M | -7.41 M | - | -5.64 M | -5.32 M | -4.38 M | - | -4.61 M | -4.68 M | -4.49 M | - | -4.03 M | -3.44 M | -3.31 M | - | -2.2 M | -2.45 M | -2.02 M | - | -2 M | -2.18 M | -3.13 M | - | -1.98 M | -1.47 M | -1.95 M | - | -2.08 M | -2.29 M | -2.4 M | - | -1.76 M | -1.77 M | -2.03 M | - | -3.41 M | -3.57 M | -4.89 M | - | -6.48 M | -7.24 M | -5.54 M | - | -3.88 M | -4.22 M | -3.88 M | -4.37 M | -3.28 M | -7.65 M | -3.28 M | -8.24 M | -2.15 M | -2.17 M | -1.17 M |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 119 K | 119 K | - | 197 K | 188 K | 179 K | - | 246 K | 275 K | 301 K | - | 361 K | 359 K | 352 K | - | 2.16 M | 884 K | 1.28 M | 1.12 M | 988 K | 2.11 M | 988 K | 10 K | 15 K | - | - |
EBITDA |
-13.8 M | - | - | -11.4 M | - | - | - | -7.34 M | - | - | - | -4.33 M | - | -4.48 M | -4.6 M | -4.44 M | - | -3.91 M | -3.36 M | -3.26 M | - | -2.07 M | -2.36 M | -1.97 M | - | -1.88 M | -2.11 M | -3.1 M | - | -1.86 M | -1.39 M | -1.91 M | - | -1.96 M | -2.21 M | -2.36 M | - | -1.62 M | -1.67 M | -1.98 M | - | -3.22 M | -3.44 M | -4.82 M | - | -6.3 M | -7.11 M | -5.48 M | - | -3.72 M | -4.1 M | -3.83 M | -4.37 M | -3.25 M | -7.55 M | -3.25 M | -8.24 M | -2.14 M | -2.17 M | -1.14 M |
Operating Expenses |
14.7 M | 13.9 M | 13.3 M | 11.8 M | - | 8.88 M | 8.59 M | 7.71 M | - | 6.08 M | 5.81 M | 4.75 M | - | 4.98 M | 5.11 M | 4.61 M | - | 4.12 M | 3.7 M | 3.42 M | - | 2.49 M | 2.33 M | 2.32 M | - | 2.12 M | 2.62 M | 3.06 M | - | 2.18 M | 1.75 M | 2.25 M | - | 2.24 M | 2.44 M | 2.48 M | - | 1.79 M | 1.83 M | 2.1 M | - | 3.5 M | 3.36 M | 4.85 M | - | 6.4 M | 6.84 M | 6.39 M | - | 4.69 M | 4.88 M | 4.69 M | 5.17 M | 3.56 M | 8.73 M | 3.56 M | 8.86 M | 3.34 M | 2.57 M | 1.96 M |
General and Administrative Expenses |
4.72 M | 5.89 M | 5.33 M | 4.94 M | - | 3.49 M | 3.74 M | 3.84 M | - | 3.09 M | 2.92 M | 2.12 M | - | 2.07 M | 2.07 M | 2.18 M | - | 1.83 M | 1.78 M | 1.87 M | - | 1.46 M | 1.5 M | 1.17 M | - | 1.15 M | 1.14 M | 1.3 M | - | 1.16 M | 940 K | 1.5 M | - | 1.28 M | 1.41 M | 1.6 M | - | 1.19 M | 1.15 M | 1.35 M | - | 1.71 M | 1.59 M | 1.97 M | - | 2.14 M | 2.45 M | 2.54 M | - | 2.31 M | 2.63 M | 2.31 M | 1.79 M | 2.21 M | 4 M | 2.21 M | 7.4 M | 2.49 M | 1.2 M | 1.19 M |
All numbers in USD currency
Main types of financial statements InspireMD NSPRFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting InspireMD plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
AxoGen
AXGN
|
$ 43.32 | 0.04 % | $ 1.99 B | ||
|
Bruker Corporation
BRKR
|
$ 59.67 | 0.18 % | $ 9.06 B | ||
|
Cognyte Software Ltd.
CGNT
|
$ 8.73 | 1.16 % | $ 637 M | ||
|
ClearPoint Neuro
CLPT
|
$ 14.97 | 13.03 % | $ 424 M | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
CONMED Corporation
CNMD
|
$ 45.8 | 3.31 % | $ 1.42 B | ||
|
Cytosorbents Corporation
CTSO
|
$ 4.91 | 0.75 % | $ 306 M | ||
|
Delcath Systems
DCTH
|
$ 15.96 | 1.8 % | $ 572 M | ||
|
Eargo
EAR
|
- | - | $ 10.2 M | ||
|
AdaptHealth Corp.
AHCO
|
$ 5.7 | 0.43 % | $ 770 M | ||
|
Electromed
ELMD
|
$ 27.57 | 0.11 % | $ 228 M | ||
|
Establishment Labs Holdings
ESTA
|
$ 67.76 | 3.69 % | $ 2.01 B | ||
|
Edwards Lifesciences Corporation
EW
|
$ 86.82 | 0.51 % | $ 50.8 B | ||
|
Align Technology
ALGN
|
$ 148.17 | 4.36 % | $ 10.7 B | ||
|
Helius Medical Technologies
HSDT
|
$ 2.88 | 2.45 % | $ 63.5 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 15.53 | 2.76 % | $ 1.19 B | ||
|
Inogen
INGN
|
$ 5.09 | 2.55 % | $ 135 M | ||
|
Inspire Medical Systems
INSP
|
$ 69.06 | 0.57 % | $ 2.03 B | ||
|
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.08 % | $ 10.7 M | ||
|
IRadimed Corporation
IRMD
|
$ 86.35 | 0.08 % | $ 1.1 B | ||
|
Integer Holdings Corporation
ITGR
|
$ 126.32 | 0.02 % | $ 4.39 B | ||
|
LENSAR
LNSR
|
$ 7.15 | 0.14 % | $ 85.5 M | ||
|
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | ||
|
Apyx Medical Corporation
APYX
|
$ 2.95 | 1.37 % | $ 121 M | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
Medtronic PLC
MDT
|
$ 89.3 | 0.08 % | $ 114 B | ||
|
MiMedx Group
MDXG
|
$ 4.77 | 0.2 % | $ 705 M | ||
|
Accuray Incorporated
ARAY
|
$ 0.23 | 1.0 % | $ 28.2 M | ||
|
Myomo
MYO
|
$ 1.64 | 0.3 % | $ 68.6 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 0.7 | 0.45 % | $ 45.4 M | ||
|
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | ||
|
Orthofix Medical
OFIX
|
$ 9.18 | 2.23 % | $ 364 M | ||
|
Outset Medical
OM
|
$ 3.09 | 5.45 % | $ 47 K | ||
|
Boston Scientific Corporation
BSX
|
$ 44.62 | 0.31 % | $ 66.1 B | ||
|
Insulet Corporation
PODD
|
$ 136.49 | 0.01 % | $ 9.6 B | ||
|
Profound Medical Corp.
PROF
|
$ 5.74 | 0.16 % | $ 174 M | ||
|
Quanterix Corporation
QTRX
|
$ 3.16 | 4.93 % | $ 135 M | ||
|
AVITA Medical
RCEL
|
$ 10.95 | 0.61 % | $ 305 M | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
$ 1.78 | 3.98 % | $ 4.94 M | ||
|
Smith & Nephew plc
SNN
|
$ 26.82 | 0.07 % | $ 23.3 B | ||
|
Inari Medical
NARI
|
- | - | $ 4.23 B | ||
|
Sensus Healthcare
SRTS
|
$ 3.03 | 0.32 % | $ 49.5 M | ||
|
Stryker Corporation
SYK
|
$ 273.4 | 0.38 % | $ 104 B | ||
|
Tactile Systems Technology
TCMD
|
$ 22.43 | 0.55 % | $ 513 M | ||
|
TELA Bio
TELA
|
$ 1.3 | 0.71 % | $ 61 M | ||
|
Viemed Healthcare
VMD
|
$ 8.8 | 1.24 % | $ 342 M | ||
|
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | ||
|
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M |